Evidence map›Paper›PMID 17693596›Full record

ArticleEukaryotic cell2007

Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates.

Alix Coste, Anna Selmecki, Anja Forche, Dorothée Diogo, Marie-Elisabeth Bougnoux, Christophe d'Enfert, Judith Berman, Dominique Sanglard

Open access · diamondAbstract read
In one paragraph

Article in Eukaryotic cell, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 303 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Analysis of clinicalAntimicrobial agents and chemotherapy · 2024
    Article
  17. Article
  18. Article
  19. Analysis of clinicalbioRxiv : the preprint server for biology · 2023
    Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Alix CosteInstitute of Microbiology, University of Lausanne and University Hospital Center, Rue du Bugnon 48, CH-1011, Lausanne, Switzerland.
Anna Selmecki
Anja Forche
Dorothée Diogo
Marie-Elisabeth Bougnoux
Christophe d'Enfert
Judith Berman
Dominique Sanglard
Institut Pasteur · FRUniversity of Minnesota · USUniversity of Lausanne · CH

Funding

Genome Integrity in Candida albicansR01AI062427 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BERMAN, JUDITH G. · 2005 to 2014
$3.6M
NIAID NIH HHS AI62427NIAID NIH HHS R01 AI062427
6 · The paper itself

Abstract

TAC1 (for transcriptional activator of CDR genes) is critical for the upregulation of the ABC transporters CDR1 and CDR2, which mediate azole resistance in Candida albicans. While a wild-type TAC1 allele drives high expression of CDR1/2 in response to inducers, we showed previously that TAC1 can be hyperactive by a gain-of-function (GOF) point mutation responsible for constitutive high expression of CDR1/2. High azole resistance levels are achieved when C. albicans carries hyperactive alleles only as a consequence of loss of heterozygosity (LOH) at the TAC1 locus on chromosome 5 (Chr 5), which is linked to the mating-type-like (MTL) locus. Both are located on the Chr 5 left arm along with ERG11 (target of azoles). In this work, five groups of related isolates containing azole-susceptible and -resistant strains were analyzed for the TAC1 and ERG11 alleles and for Chr 5 alterations. While recovered ERG11 alleles contained known mutations, 17 new TAC1 alleles were isolated, including 7 hyperactive alleles with five separate new GOF mutations. Single-nucleotide-polymorphism analysis of Chr 5 revealed that azole-resistant strains acquired TAC1 hyperactive alleles and, in most cases, ERG11 mutant alleles by LOH events not systematically including the MTL locus. TAC1 LOH resulted from mitotic recombination of the left arm of Chr 5, gene conversion within the TAC1 locus, or the loss and reduplication of the entire Chr 5. In one case, two independent TAC1 hyperactive alleles were acquired. Comparative genome hybridization and karyotype analysis revealed the presence of isochromosome 5L [i(5L)] in two azole-resistant strains. i(5L) leads to increased copy numbers of azole resistance genes present on the left arm of Chr 5, among them TAC1 and ERG11. Our work shows that azole resistance was due not only to the presence of specific mutations in azole resistance genes (at least ERG11 and TAC1) but also to their increase in copy number by LOH and to the addition of extra Chr 5 copies. With the combination of these different modifications, sophisticated genotypes were obtained. The development of azole resistance in C. albicans is therefore a powerful instrument for generating genetic diversity.

Indexed as

Evolution, MolecularAllelesAneuploidyAzolesCandida albicansChromosome MappingChromosomes, FungalDrug Resistance, FungalFungal ProteinsGene ConversionGene DosageGene DuplicationGenotypeMicrobial Sensitivity TestsMitosisMutationAzolesFungal Proteins

Identifiers

PMID17693596
PMCPMC2043391
OpenAlexW2131635397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.